KH631

KH631 is an investigational gene therapy for neovascular (wet) age-related macular degeneration (nAMD). It uses a recombinant adeno-associated virus 8 (rAAV8) vector to deliver a transgene encoding a human VEGF receptor fusion protein. This fusion protein consists of domain 2 of VEGFR1, domains 3 and 4 of VEGFR2, and the Fc domain of human IgG1. The expressed protein binds and inhibits vascular endothelial growth factor A (VEGF-A), VEGF-B, and placental growth factor (PlGF), thereby blocking angiogenesis in the retina. KH631 is administered as a single subretinal injection with the goal of providing long-term suppression of pathological neovascularization, potentially reducing or eliminating the need for frequent anti-VEGF injections. The therapy is being developed by Chengdu Kanghong Pharmaceutical for wet AMD and has entered phase I/II clinical trials in China and the United States[1][2][3][4][5][7].